EMD Serono and Open Monoclonal Technology Expand Collaboration to Include Unlimited Access to OmniRat® Human Antibody Platform

  EMD Serono and Open Monoclonal Technology Expand Collaboration to Include
  Unlimited Access to OmniRat® Human Antibody Platform

Business Wire

PALO ALTO, Calif. -- October 28, 2013

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, and Open
Monoclonal Technology, Inc. (OMT), a leader in the genetic engineering of
animals for development of human therapeutic antibodies, today announced
expansion of their collaboration agreement from June 2012. Under the terms of
the new agreement, EMD Serono will make an upfront payment to secure unlimited
access to the OmniRat platform as well as success-based development milestones
and royalties. Further details of the contract are not being disclosed.

“The expansion of our collaboration with OMT is reflective of its strong
quality and the significant progress we've made together over the last 15
months," said Dr. Annalisa Jenkins, Executive Vice President and head of
Global Research & Development for Merck Serono, a biopharmaceutical division
of Merck KGaA, Darmstadt, Germany. “This is a good example of our focus on
exploring targeted partnerships with innovative companies such as OMT, with
the goal of generating access to technologies that advance our capabilities in
biotech development.”

Dr. Roland Buelow, founder and CEO of OMT, said: "EMD Serono’s transition to
unlimited platform access is evidence of their success with OmniRat on
multiple therapeutic targets during the past 15 months. The expansion
illustrates how OMT provides its partners with access to complementary
platforms for discovery of superior antibodies against challenging targets in
a cost-effective fashion.”

About Merck KGaA

Merck is a leading pharmaceutical, chemical and life science company with
total revenues of € 11.2 billion in 2012, a history that began in 1668, and a
future shaped by approximately 38,000 employees in 66 countries. Its success
is characterized by innovations from entrepreneurial employees. Merck's
operating activities come under the umbrella of Merck KGaA, in which the Merck
family holds an approximately 70% interest and free shareholders own the
remaining approximately 30%. In 1917 the US subsidiary Merck & Co. was
expropriated and has been an independent company ever since. For more
information, please visit www.merckserono.com or www.merckgroup.com.

About EMD Serono, Inc.

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a
specialized biopharmaceutical company dedicated to developing therapies with
ground breaking potential. The company has strong market positions in
neurology, endocrinology and reproductive health. In addition, EMD Serono has
an enduring commitment to solve the unsolvable, with state-of-the-art science
dedicated to developing new therapies in the core focus areas of neurology,
oncology, immune oncology and immunology. With a long-standing history of
industry expertise and a dedication to shape the future of healthcare, the
company’s US footprint continues to grow, with approximately 1,000 employees
around the country and fully integrated commercial, clinical and research
operations in its home state, Massachusetts. For more information, please
visit www.emdserono.com.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of
animals for discovery of human therapeutic antibodies – naturally optimized
human antibodies^®.

OMT has created OmniRat^®, the industry’s first fully human monoclonal
antibody platform based on rats. It represents a novel and proprietary
technology with unrestricted development options. OMT and Pfizer have
demonstrated that OmniRat has a complete immune system with a diverse antibody
repertoire and generates antibodies with human idiotypes as well as a
wild-type animals make rat antibodies (Journal of Immunology 2013 Feb 15;
190(4):1481-90).

OmniMouse^® is a transgenic mouse designed to complement OmniRat and further
increase epitope coverage. Both animals deliver antibodies with great
affinity, specificity, expression, solubility and stability, yet with low or
no immunogenicity or need for lead optimization. OmniFlic^™ is the industry’s
first engineered rat with a fixed light chain for development of human
bispecific antibodies.

OMT’s antibody platforms have broad freedom to operate and use technology
protected by new patents and patent applications. They are available for
licensing worldwide for all targets and indications and are now partnered with
Janssen, Merck KGaA, Pfizer, Symphogen, WuXi and other biopharmaceutical
companies. For more information, please visit www.omtinc.net.

Contact:

Open Monoclonal Technology, Inc.
Brian Lundstrom, +1-775-420-7750
Chief Business Officer
bl@omtinc.net
www.omtinc.net
 
Press spacebar to pause and continue. Press esc to stop.